Quinoline compounds

Details Quinoline compounds Quinoline compounds

2011-08-30

2011-08-30

Chu, Yong (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S311000, C514S312000, C514S314000, C544S353000, C546S153000, C546S173000, C546S152000

Reexamination Certificate

active

08008306

ABSTRACT:
To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease.A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.

REFERENCES:
patent: 2005/0215577 (2005-09-01), Dehmlow
patent: 527433 (1993-02-01), None
patent: 2002-539155 (2002-11-01), None
patent: 2004-509161 (2004-03-01), None
patent: 00/54759 (2000-09-01), None
patent: 02/24632 (2002-03-01), None
patent: 03/082192 (2003-10-01), None
patent: 2004/024161 (2004-03-01), None
patent: 2004/058717 (2004-07-01), None
patent: 2004/072046 (2004-08-01), None
patent: 2005/023188 (2005-03-01), None
patent: 2005/058834 (2005-06-01), None
Byrn et al. Solid-State Chemistry of Drugs, 2d, Chapter 11 Hydrates and Solvates, 233-247 (1999).
Morissette et al. Adv. Drug Delivery Rev. 2004, 56, 275-300.
A.M. Rouhi, Chem. & Eng. News, Feb. 24, 2003, 81(8), 32-35.
Schafer et al. Drug Discovery Today, 13:913 (2008).
Horig et al. Journal of Translational Medicine, 2:44 (2004).
G. Cao et al., “Antidiabetic Action of a Liver X Receptor Agonist Mediated by Inhibition of Hepatic Gluconeogenesis”, The Journal of Biological Chemistry, Jan. 10, 2003, pp. 1131-1136, vol. 278, No. 10.
M. N. Bradley et al., “LXR: A nuclear receptor target for cardiovascular disease?”, Drug Discovery Today: Therapeutic Strategies, 2005, pp. 97-103, vol. 2, No. 2.
N. Zelcer et al., “Liver X receptors as integrators of metabolic and inflammatory signaling”, The Journal of Clinical Investigation, Mar. 2006, pp. 607-614, vol. 116, No. 3.
N. Terasaka et al., “T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice”, Federation of European Biochemical Societies, 2003, pp. 6-11, Letters 536.
R. K. Tangirala et al., “Identification of macrophage liver X receptors as inhibitors of atherosclerosis”, PNAS, Sep. 3, 2002, pp. 11896-11901, vol. 99, No. 18.
J. R. Schultz et al., “Role of LXRs in control of lipogenesis”, Genes & Development, 2002, pp. 2831-2838.
P. H. E. Groot et al., “Synthetic LXR agonists increase LDL in CETP species”, Journal of Lipid Research, 2005, pp. 2182-2191, vol. 46.
D. J. Peet et al, “Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα”, Cell, May 29, 1998, pp. 693-704, vol. 93.
S. B. Joseph et al., “Reciprocal regulation of inflammation and lipid metabolism by liver X receptors”, Nature Medicine, Feb. 2003, pp. 213-219, vol. 9, No. 2.
E. G. Lund et al., “Liver X Receptor Agonists as Potential Therapeutic Agents for Dyslipidemia and Atherosclerosis”, Arterioscler Thromb Vasc Biol, Jul. 2003, pp. 1169-1177.
D. Auboeuf et al., “Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator-Activated Receptors and Liver X Receptor-in Humans”, Diabetes, Aug. 1997, pp. 1319-1327, vol. 46.
S. Alberti et al., “Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice”, The Journal of Clinical Investigation, Mar. 2001, pp. 565-573, vol. 107, No. 5.
B. Hu et al., “Further modification on phenyl acetic acid based quinolines as liver X receptor modulators”, Bioorganic & Medicinal Chemistry, 2007, pp. 3321-3333, vol. 15.
B. Hu et al., “Carboxylic acid based quinolines as liver X receptor modulators that have LXRβ receptor binding selectivity”, Bioorganic & Medicinal Chemistry Letters, 2007, pp. 54-59, vol. 18.
X. Fu et al., “27-Hydroxycholesterol is an Endogenous Ligand for Liver X Receptor in Cholesterol-loaded Cells”, The Journal of Biological Chemistry, 2001, pp. 38378-38387, vol. 276, No. 42.
R. Geyeregger et al., “Liver X receptors in cardiovascular and metabolic disease”, Cellular and Molecular Life Sciences, 2006, pp. 524-539, vol. 63.
B. A. Janowski et al, “An oxysterol signalling pathway mediated by the nuclear receptor LXRα”, Nature, Oct. 24, 1996, pp. 728-731, vol. 383.
B. Hu et al., “Discovery of Phenyl Acetic Acid Substituted Quinolines as Novel Liver X Receptor Agonists for the Treatment of Atherosclerosis”, Journal of Medicinal Chemistry, Sep. 9, 2006, pp. 6151-6154, vol. 49.
T. T. Lu et al., Orphan Nuclear Receptors as eLiXiRs and FiXeRs of Sterol Metabolism, The Journal of Biological Chemistry, 2001, pp. 37735-37738, vol. 276, No. 41.
D. S. Lala, “The liver X receptors”, Current Opinion in Investigational Drugs, 2005, pp. 934-943, vol. 6, No. 9.
J. M. Lehmann et al., “Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway”, The Journal of Biological Chemistry, 1997, pp. 3137-3140, vol. 272, No. 6.
B. A. Laffitte et al., “Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue”, PNAS, Apr. 29, 2003, pp. 5419-5424, vol. 100, No. 9.

Affiliated with

Also associated with

Rating

Quinoline compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoline compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2669961